BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21471424)

  • 1. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
    Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
    Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Afzal S; Gusella M; Jensen SA; Vainer B; Vogel U; Andersen JT; Brødbæk K; Petersen M; Jimenez-Solem E; Adleff V; Budai B; Hitre E; Láng I; Orosz E; Bertolaso L; Barile C; Padrini R; Kralovánszky J; Pasini F; Poulsen HE
    Pharmacogenomics; 2011 Sep; 12(9):1257-67. PubMed ID: 21919605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
    Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
    Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
    Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].
    Gao CM; Lu JW; Toshiro T; Wu JZ; Cao HX; Chen HQ; Feng JF; Kazuo T
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Dec; 25(12):1054-8. PubMed ID: 15769364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
    Ichikawa W; Takahashi T; Suto K; Sasaki Y; Hirayama R
    Clin Cancer Res; 2006 Jul; 12(13):3928-34. PubMed ID: 16818689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
    Rumiato E; Boldrin E; Amadori A; Saggioro D
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
    Shitara K; Muro K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Matsuo K
    Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1311-9. PubMed ID: 20447923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
    Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
    Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
    Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
    Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
    Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
    Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer.
    Taflin H; Wettergren Y; Odin E; Carlsson G; Derwinger K
    Anticancer Res; 2011 Sep; 31(9):3057-62. PubMed ID: 21868559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
    Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.